BSLN Analyst Estimates: Price Targets, Revenue, Net Income, and EBIT Forecast - Basilea Pharmaceutica AG - Alpha Spread

Basilea Pharmaceutica AG
SIX:BSLN

Watchlist Manager
Basilea Pharmaceutica AG Logo
Basilea Pharmaceutica AG
SIX:BSLN
Watchlist
Price: 45.15 CHF -0.22% Market Closed
Market Cap: 545m CHF
Have any thoughts about
Basilea Pharmaceutica AG?
Write Note

Wall Street
Price Targets

BSLN Price Targets Summary
Basilea Pharmaceutica AG

Wall Street analysts forecast BSLN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for BSLN is 65.54 CHF with a low forecast of 47.47 CHF and a high forecast of 98.7 CHF.

Lowest
Price Target
47.47 CHF
5% Upside
Average
Price Target
65.54 CHF
45% Upside
Highest
Price Target
98.7 CHF
119% Upside
Basilea Pharmaceutica AG Competitors:
Price Targets
ABIO
ARCA Biopharma Inc
192% Upside
ALERS
Eurobio Scientific SA
22% Upside
DVYSR
Devyser Diagnostics AB
9% Upside
GRTS
Gritstone bio Inc
682% Upside
MYGN
Myriad Genetics Inc
12% Upside
87S
Roivant Sciences Ltd
35% Upside
006280
Green Cross Corp
10% Upside
ALLO
Allogene Therapeutics Inc
298% Upside

Revenue
Forecast

Revenue Estimate
Basilea Pharmaceutica AG

For the last 8 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 15%. The projected CAGR for the next 3 years is 16%.

15%
Past Growth
16%
Estimated Growth
Estimates Accuracy
3%
Average Beat

Operating Income
Forecast

Operating Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 3 years is 53%.

N/A
Past Growth
53%
Estimated Growth
Estimates Accuracy
-13%
Average Miss

Net Income
Forecast

Net Income Estimate
Basilea Pharmaceutica AG

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 3 years is 84%.

N/A
Past Growth
84%
Estimated Growth
Estimates Accuracy
-23%
Average Miss

See Also

Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What is available on other sites you are seeing are mostly from the sell-side analysts.

What is BSLN's stock price target?
Price Target
65.54 CHF

According to Wall Street analysts, the average 1-year price target for BSLN is 65.54 CHF with a low forecast of 47.47 CHF and a high forecast of 98.7 CHF.

What is Basilea Pharmaceutica AG's Revenue forecast?
Projected CAGR
16%

For the last 8 years the compound annual growth rate for Basilea Pharmaceutica AG's revenue is 15%. The projected CAGR for the next 3 years is 16%.

What is Basilea Pharmaceutica AG's Operating Income forecast?
Projected CAGR
53%

The compound annual growth rate of Basilea Pharmaceutica AG's operating income for the next 3 years is 53%.

What is Basilea Pharmaceutica AG's Net Income forecast?
Projected CAGR
84%

The compound annual growth rate of Basilea Pharmaceutica AG's net income for the next 3 years is 84%.

Back to Top